Tolerance to self and the processing and presentation of self antigens

Expression of autoimmune disease-related antigens by cells of the immune system

The process of thymic selection is critical for the generation of the mature T-cell repertoire, yet the nature of the self-peptides that serve this function is not known. Several studies suggest that tissue-specific auto-antigens are expressed in the thymus. We initiated this study to examine the expression of a panel of auto-antigens related to several autoimmune diseases in the thymus, peripheral lymphoid organs, and various cell lines. We looked for the expression of these antigens by reverse transcriptase-polymerase chain reaction, fluorescence-activated cell sorter (FACS) analysis, immunoblotting, and immunoprecipitation. We found that in the thymus there is evidence for the expression of a wide variety of disease-related self-antigens including myelin antigens, insulin, cardiac myosin, and retinal S antigen. By FACS analysis, several monoclonal anti-myelin basic protein antibodies were found to bind to immune cells. In Western blotting, we could find in the thymus and other lymphoid organs the expression of myelin basic protein, proteolipid protein, and cyclic nucleotide phosphodiesterase; in contrast, the staining for myelin oligodendrocyte glycoprotein, microtubule-associated Tau protein, and insulin were negative in these organs. The results of these studies confirm that there is evidence for the expression of a variety of auto-antigens in the immune system, both at the mRNA and protein levels, potentially enabling them to participate in the process of thymic education.

Regulation of autoimmune diabetes: characteristics of non-islet-antigen specific therapies

Non-islet-antigen specific treatments have been shown to alter the natural history of insulin dependent diabetes in both the non-obese diabetic (NOD) mouse and in recently diagnosed patients. However concerns have been raised regarding the possibility that non-islet-antigen specific therapy may trade cell mediated autoimmunity for antibody dependent autoimmunity. Female NOD mice at approximately 70 days of age were treated with the non-islet-antigen specific agents complete Freund's adjuvant (CFA) and Bacillus Calmette-Guerin (BCG) and assayed for the development of antibody mediated autoimmunity at 300 days of age. Autoantibodies to red cells were not detected in any of the BCG (n = 19) or CFA (n = 15) treated animals, while 2 of 13 age-matched NOD animals had autoantibodies to red cells, shown by a positive direct Coomb's test. Anti-nuclear autoantibodies and complement deposition in the renal glomeruli were not significantly increased in the treated animals as compared to age-matched non-diabetic mice. The relative effectiveness of CFA and BCG treatment was examined in terms of the ability of these agents to preserve insulin containing islets. Complete Freund's adjuvant treatment was found to be more effective in preserving insulin containing islets when compared to BCG treatment. This study demonstrates that it is possible to inhibit the development of autoimmune diabetes without increasing the probability that treated animals will develop antibody dependent autoimmunity.